PharmaLundensis AB Logo

PharmaLundensis AB

Develops treatments for heavy metal toxicity and serious respiratory illnesses.

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is PHAL-501, a drug designed to bind and excrete heavy metals like mercury, lead, and cadmium from the body. PHAL-501 is intended to act within the intestine, capturing toxins before they are absorbed into the bloodstream, thus offering a potentially safe and effective treatment for heavy metal toxicity. In addition to this focus, the company is also involved in developing therapies for serious respiratory illnesses, such as chronic obstructive pulmonary disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaLundensis AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

Company Country Ticker View
DT&CRO CO., Ltd. Logo
A full-service CRO for pharma & biotech, from non-clinical studies to FDA approval support.
South Korea 383930
DUSKIN CO.,LTD. Logo
Franchises cleaning rentals and services for homes and businesses, and operates food chains.
Japan 4665
D.Western Therapeutics Institute, Inc. Logo
Biotech firm discovering and licensing drug candidates, focusing on kinase inhibitors.
Japan 4576
ECHOMARKETING Co.,Ltd. Logo
Global agency accelerating sales with data-driven, full-funnel digital marketing.
South Korea 230360
Eezy Oyj Logo
HR services firm for the full employment lifecycle, from recruitment to freelancer support.
Finland EEZY
Enjin Co., Ltd. Logo
PR firm for SMEs and medical institutions, offering consulting and a media matching platform.
Japan 7370
Ensol Biosciences Inc. Logo
Develops AI-discovered peptide drugs for cancer, osteoarthritis, and Alzheimer's disease.
South Korea 140610
Eutilex Co.,Ltd. Logo
Develops T-cell and antibody immunotherapies for cancer and autoimmune diseases.
South Korea 263050
Evogene Ltd. Logo
AI-powered platform designing life-science solutions for health, ag, and industrial sectors.
Israel EVGN
EXACT Therapeutics AS Logo
Biopharma firm using ultrasound to enhance drug delivery for oncology via its ACT® platform.
Norway EXTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.